Moving Past the Barriers: Understanding Why Black Women Are Underrepresented in Clinical Trials

A straightforward query generated complex responses: "Would you enroll in a clinical trial?" Baltimore resident Kim Pennington expressed her apprehension, stating, “I would be nervous. It requires sacrifice, and I’m unsure if I'm willing to jeopardize my health for an experiment.” This sentiment resonates widely. Only 2% of cancer clinical trial participants are Black women, contributing to their 38% increased likelihood of dying from breast cancer. Clinical trials are vital, allowing volunteers to test new medications, thus enabling research on safety and efficacy. Dr. Georges C. Benjamin, executive director of the American Public Health Association, highlights their importance for accessing cutting-edge treatments.Secondarily, a historical context of exploitation fosters mistrust. A recent survey revealed that lack of recruitment, alongside fears of being treated as “guinea pigs,” further inhibits participation. Initiatives like "When We Tri(al)" aim to bridge this gap, enabling enhanced representation and understanding of breast cancer in Black women, ultimately advancing medical research.